Literature DB >> 17591434

Interleukin-6 as a mechanism for the adverse effects of social stress on acute Theiler's virus infection.

Mary W Meagher1, Robin R Johnson, Erin E Young, Elisabeth G Vichaya, Shannon Lunt, Elizabeth A Hardin, Marilyn A Connor, C Jane R Welsh.   

Abstract

Prior exposure to social disruption stress (SDR) exacerbates both the acute and chronic phase of Theiler's murine encephalomyelitis virus infection (TMEV; [Johnson, R.R., Storts, R., Welsh, T.H., Jr., Welsh, C.J., Meagher, M.W., 2004. Social stress alters the severity of acute Theiler's virus infection. J. Neuroimmunol. 148, 74--85; Johnson, R.R., Prentice, T.W., Bridegam, P., Young, C.R., Steelman, A.J., Welsh, T.H., Welsh, C.J.R., Meagher, M.W., 2006. Social stress alters the severity and onset of the chronic phase of Theiler's virus infection. J. Neuroimmunol. 175, 39--51]). However, the neuroimmune mechanism(s) mediating this effect have not been determined. The present study examined whether stress-induced increases in the proinflammatory cytokine interleukin-6 (IL-6) contributes to the adverse effects of SDR on acute TMEV infection. Experiment 1 demonstrated that SDR increases central and peripheral levels of IL-6 and that this effect is reversed by intracerebral ventricular infusion of neutralizing antibody to IL-6 prior to each of six SDR sessions. Although SDR reduced the sensitivity of spleen cells to the anti-inflammatory effects of corticosterone, the neutralizing antibody to IL-6 did not alter this effect. To investigate whether stress-induced increases in IL-6 contribute to the exacerbation of acute TMEV infection, Experiment 2 examined whether intracerebral administration of neutralizing antibody to IL-6 during SDR would prevent the subsequent exacerbation of acute TMEV infection. Experiment 3 then replaced the social stress with intracerebral infusion of IL-6 to assess sufficiency. As expected, prior exposure to SDR subsequently increased infection-related sickness behaviors, motor impairment, CNS viral titers, and CNS inflammation. These deleterious effects of SDR were either prevented or significantly attenuated by intracerebral infusion of neutralizing antibody to IL-6 during the stress exposure period. However, infusion of IL-6 alone did not mimic the adverse effects of SDR. We conclude that IL-6 is necessary but not sufficient to exacerbate acute TMEV infection.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17591434      PMCID: PMC2538675          DOI: 10.1016/j.bbi.2007.05.001

Source DB:  PubMed          Journal:  Brain Behav Immun        ISSN: 0889-1591            Impact factor:   7.217


  95 in total

1.  Stressful life events precede exacerbations of multiple sclerosis.

Authors:  Kurt D Ackerman; Rock Heyman; Bruce S Rabin; Barbara P Anderson; Patricia R Houck; Ellen Frank; Andrew Baum
Journal:  Psychosom Med       Date:  2002 Nov-Dec       Impact factor: 4.312

2.  Social disruption-induced glucocorticoid resistance: kinetics and site specificity.

Authors:  Ronit Avitsur; Jennifer L Stark; Firdaus S Dhabhar; David A Padgett; John F Sheridan
Journal:  J Neuroimmunol       Date:  2002-03       Impact factor: 3.478

3.  Prior stressor exposure primes the HPA axis.

Authors:  John D Johnson; Kevin A O'Connor; Terrence Deak; Robert L Spencer; Linda R Watkins; Steven F Maier
Journal:  Psychoneuroendocrinology       Date:  2002-04       Impact factor: 4.905

4.  Intracerebral HIV-1 glycoprotein 120 produces sickness behavior and pituitary-adrenal activation in rats: role of prostaglandins.

Authors:  Ohr Barak; Joseph Weidenfeld; Inbal Goshen; Tamir Ben-Hur; Anna N Taylor; Raz Yirmiya
Journal:  Brain Behav Immun       Date:  2002-12       Impact factor: 7.217

Review 5.  Innate immunity: the missing link in neuroprotection and neurodegeneration?

Authors:  Minh Dang Nguyen; Jean-Pierre Julien; Serge Rivest
Journal:  Nat Rev Neurosci       Date:  2002-03       Impact factor: 34.870

6.  Interleukin-6 and the development of social disruption-induced glucocorticoid resistance.

Authors:  Jennifer L Stark; Ronit Avitsur; John Hunzeker; David A Padgett; John F Sheridan
Journal:  J Neuroimmunol       Date:  2002-03       Impact factor: 3.478

7.  Involvement of brain cytokines in the neurobehavioral disturbances induced by HIV-1 glycoprotein120.

Authors:  Ohr Barak; Inbal Goshen; Tamir Ben-Hur; Joseph Weidenfeld; Anna N Taylor; Raz Yirmiya
Journal:  Brain Res       Date:  2002-04-19       Impact factor: 3.252

8.  Stress, glucocorticoids and the susceptibility to develop autoimmune disorders of the central nervous system.

Authors:  C Morale; J Brouwer; N Testa; C Tirolo; N Barden; C D Dijkstra; S Amor; B Marchetti
Journal:  Neurol Sci       Date:  2001-04       Impact factor: 3.307

9.  The significance of environmental factors in the etiology of Alzheimer's disease.

Authors:  William B Grant; Arezoo Campbell; Ruth F Itzhaki; John Savory
Journal:  J Alzheimers Dis       Date:  2002-06       Impact factor: 4.472

10.  Prior stressor exposure sensitizes LPS-induced cytokine production.

Authors:  John D Johnson; Kevin A O'Connor; Terrence Deak; Matt Stark; Linda R Watkins; Steven F Maier
Journal:  Brain Behav Immun       Date:  2002-08       Impact factor: 7.217

View more
  18 in total

1.  Social disruption induced priming of CNS inflammatory response to Theiler's virus is dependent upon stress induced IL-6 release.

Authors:  E G Vichaya; E E Young; M A Frazier; J L Cook; C J Welsh; M W Meagher
Journal:  J Neuroimmunol       Date:  2011-10-13       Impact factor: 3.478

2.  Glucocorticoid exposure alters the pathogenesis of Theiler's murine encephalomyelitis virus during acute infection.

Authors:  Erin E Young; Thomas W Prentice; Danielle Satterlee; Heath McCullough; Amy N Sieve; Robin R Johnson; Thomas H Welsh; C Jane R Welsh; Mary W Meagher
Journal:  Physiol Behav       Date:  2008-05-07

3.  Characterization of 3(3,4-dihydroxy-phenyl) propionic acid as a novel microbiome-derived epigenetic modifier in attenuation of immune inflammatory response in human monocytes.

Authors:  Jun Wang; Jennifer Blaze; Fatemeh Haghighi; Seunghee Kim-Schulze; Urdvha Raval; Kyle J Trageser; Giulio Maria Pasinetti
Journal:  Mol Immunol       Date:  2020-07-21       Impact factor: 4.407

4.  Chronic social stress impairs virus specific adaptive immunity during acute Theiler's virus infection.

Authors:  Erin E Young; Elisabeth G Vichaya; Nicole M Reusser; Jennifer L Cook; Andrew J Steelman; C Jane R Welsh; Mary W Meagher
Journal:  J Neuroimmunol       Date:  2012-09-27       Impact factor: 3.478

5.  Immunogenic dendritic cells primed by social defeat enhance adaptive immunity to influenza A virus.

Authors:  Nicole D Powell; Jacqueline W Mays; Michael T Bailey; Mark L Hanke; John F Sheridan
Journal:  Brain Behav Immun       Date:  2010-07-23       Impact factor: 7.217

Review 6.  The Role of the Gut Microbiota in the Metabolism of Polyphenols as Characterized by Gnotobiotic Mice.

Authors:  Giulio Maria Pasinetti; Risham Singh; Susan Westfall; Francis Herman; Jeremiah Faith; Lap Ho
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

7.  Beta adrenergic blockade decreases the immunomodulatory effects of social disruption stress.

Authors:  M L Hanke; N D Powell; L M Stiner; M T Bailey; J F Sheridan
Journal:  Brain Behav Immun       Date:  2012-07-24       Impact factor: 7.217

Review 8.  Neuroimmune mechanisms of depression.

Authors:  Georgia E Hodes; Veronika Kana; Caroline Menard; Miriam Merad; Scott J Russo
Journal:  Nat Neurosci       Date:  2015-09-25       Impact factor: 24.884

9.  Social disruption alters pain and cognition in an animal model of multiple sclerosis.

Authors:  H R Linsenbardt; J L Cook; E E Young; E G Vichaya; C R Young; N M Reusser; R Storts; C J Welsh; M W Meagher
Journal:  J Neuroimmunol       Date:  2015-09-12       Impact factor: 3.478

10.  Social isolation alters neuroinflammatory response to stroke.

Authors:  Kate Karelina; Greg J Norman; Ning Zhang; John S Morris; Haiyan Peng; A Courtney DeVries
Journal:  Proc Natl Acad Sci U S A       Date:  2009-03-23       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.